
Mescaline /
Peyote
NOT MEDICAL ADVICE. For educational purposes only. We are not doctors. Do not stop or modify any prescribed medication based on this content. Many substances discussed are Schedule I controlled substances. Dangerous interactions exist between plant medicines and psychiatric drugs — including serotonin syndrome risk (SSRIs + MAOIs) and seizure risk (Lithium + psychedelics). Always consult qualified healthcare professionals before any action. You proceed entirely at your own risk.

Key Receptors
| Receptor | Action | Clinical Use |
|---|---|---|
| 5-HT2A | Partial agonist | Primary psychedelic; depression, neuroplasticity |
| 5-HT2C | Biased agonist | Mood, appetite neutral |
| D1/D2/D3 | Low-affinity binding | Prosocial, motivation |
| α1A/α2A | Agonist | Arousal, sympathomimetic |
| SERT/NET/DAT | No affinity | No serotonin dump (unlike MDMA/SSRIs) |
Unlike MDMA and SSRIs, mescaline has no serotonin transporter (SERT) affinity — it does not dump serotonin. Its psychedelic action is purely receptor-mediated via 5-HT2A partial agonism, with unique prosocial effects from low-affinity dopamine binding and sympathomimetic arousal from adrenergic agonism.

Same Targets. Opposite Actions.
Latuda (lurasidone) and mescaline share the same receptor targets with opposite actions:
| Receptor | Latuda | Mescaline |
|---|---|---|
| 5-HT2A | Blocks (Ki=0.47nM) | Activates |
| 5-HT7 | Blocks (antidepressant) | Indirect modulation |
| 5-HT1A | Partial agonist | Upstream upregulation |
| D2 | Full antagonist | Low-affinity touch |
| BDNF | Increases over weeks | Acute surge (one session) |
“Latuda suppresses the serotonin system daily. Mescaline resets it once.”

Clinical Outcomes
Source: Agin-Liebes et al., ACS Pharmacology 2021 (n=452 naturalistic users)

16 Medications & Their Alternatives
Do not stop or modify any prescribed medication based on this content. Dangerous interactions exist between plant medicines and psychiatric drugs. Always consult qualified healthcare professionals.
| Drug (Brand) | Category | Plant Alternative | Supplement Alt | Evidence |
|---|---|---|---|---|
| Sertraline (Zoloft) | SSRI | Psilocybin; Mescaline | St. John’s Wort; Saffron; Omega-3 EPA | Strong (Psilo) |
| Escitalopram (Lexapro) | SSRI | Psilocybin (head-to-head trial) | Rhodiola; Ashwagandha KSM-66; SAMe | Strong |
| Venlafaxine (Effexor) | SNRI | MDMA therapy; Ketamine | 5-HTP; Mag Threonate; NAC | Moderate |
| Bupropion (Wellbutrin) | NDRI | Ibogaine; Psilocybin (smoking) | Tyrosine; Mucuna pruriens | Strong (Psilo+smoking) |
| Lurasidone (Latuda) | Antipsychotic | Mescaline/Peyote; Psilocybin | Lion’s Mane; Omega-3; Glycine 8g | Emerging (Mesc) |
| Quetiapine (Seroquel) | Antipsychotic | Holotropic Breathwork; Microdose | Magnesium Glycinate; L-Theanine | Emerging |
| Aripiprazole (Abilify) | Antipsychotic | Microdose Psilocybin; CBD | Bacopa; NAC; Sarcosine | Emerging |
| Alprazolam (Xanax) | Benzo | Rapéh; Breathwork; Cacao | Kava (200–300mg); GABA+L-Theanine | Moderate (Kava) |

Preparation & Integration Stack

Mescaline-Specific Readiness
How Mescaline Compares
| Medicine | Dep | Anx | PTSD | Addict | Duration | Beginner | Evidence |
|---|---|---|---|---|---|---|---|
| Mescaline/Peyote | Yes | Yes | Yes | Yes | 8–12h | Moderate | Moderate |
| Psilocybin | Yes | Yes | Yes | Yes | 4–6h | Yes | Strong |
| MDMA | Some | Some | Best | Some | 4–6h | Yes | Strong |
| Ketamine | Fastest | Some | Some | Some | 1–2h | Yes (clinical) | Strong/FDA |
| Ayahuasca | Yes | Yes | Yes | Yes | 4–8h | No | Moderate |
| Ibogaine | Some | Some | Yes | Best | 24–36h | No | Moderate |
| San Pedro | Yes | Yes | Yes | Yes | 8–14h | Moderate | Moderate |
| Microdose | Yes | Yes | Some | Yes | Sub-perceptual | Very Yes | Moderate |

Research & References
- Agin-Liebes et al. (2021) ACS Pharmacology — mescaline survey n=452
- Ishibashi et al. (2010) J Pharmacol — lurasidone receptor profile
- Wikipedia / DrugBank — lurasidone Ki values
- PMC6864602 — peyote pharmacokinetics review
- MDPI Molecules 28(24) 7942 (2023) — peyote overview
- Johns Hopkins Psychedelics Center — psilocybin + smoking
- QPS.com / Third Wave — mescaline clinical development